ODC1 and neuroblastoma: In summary, by inhibiting ODC and decreasing intracellular polyamine levels, DFMO targets a novel pathway and therefore is likely to provide a novel therapeutic strategy for maintaining long-term remission in children with high-risk neuroblastoma.